COMPANY
www.semaspace.com
www.semaspace.com: warning letter recipient for Semaglutide, as stated by public registers.
WARNING LETTER RECIPIENT
Received an FDA warning letter naming the peptide.
| Semaglutide | Finished Pharmaceuticals/Unapproved New Drug/Misbranded, 2023-10-02 Regulator FDA warning letters |
|---|
What a register states, not an endorsement or an accusation by this site. All companies.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.